All adults aged 65 and over should now have the 13-valent pneumococcal conjugate vaccine (PCV13) in addition to the 23-valent pneumococcal polysaccharide vaccine (PPSV23) to protect against pneumococcal infection, according to the 2015 Advisory Committee on Immunization Practices (ACIP) Recommended Immunization Schedule for adults being published in Annals of Internal Medicine.
Despite extensive and targeted recommendations for use of the PCV13 and PPSV23, pneumococcal infection continues to be a major cause of morbidity, including bacteremia, meningitis, and pneumonia, among older adults. Expanding use of PCV13 to all adults along with use of PPSV23 should serve as added protection against pneumococcal infection. This is the only major change from the 2014 schedule. The complete schedule, including footnote changes, is being simultaneously published in Annals of Internal Medicine and on the Centers for Disease Control and Prevention (CDC) web site at www.cdc.gov/vaccines.
Article: Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older: United States, 2015, D.K. Kim, C.B. Bridges, and K.H. Harriman, on behalf of the Advisory Committee on Immunization Practices, Annals of Internal Medicine, doi: 10.7326/M14-2755, published 2 February 2015.
Source: American College of Physicians